EVGN

Evogene
CAPPED RATING

Evogene (EVGN) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Profitability (D).

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
C+
Factor Score 2.7 / 5.0
Growth
D
Factor Score 1.4 / 5.0
Profitability
D
Factor Score 1.3 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA -0.8
Rev Growth YoY -86.3%
Gross Margin -46.8%
Price Return 3M -13.3%
Price Return 12M -44.0%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 4.3
ROE -171.8%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) D (1.4) D (1.3) C (2.4) C- (1.9) C- (1.9)
2026-08-04 C+ (2.7) D (1.4) D (1.3) C (2.4) C- (1.9) C- (2.0)
2026-08-03 C+ (2.7) C- (2.1) D+ (1.7) C (2.4) C- (2.0) C (2.2)
2026-08-02 C+ (2.7) C- (2.1) D+ (1.7) C (2.4) C- (1.9) C (2.2)